Liver-Specific Gene Expression Vector with LCR and Enhancer Elements
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for conditions like hemophilia and liver diseases face challenges in achieving sustained, high-level tissue-specific expression of therapeutic genes in the liver, with existing vectors often resulting in transient expression and immune response issues.
Innovation Solution
Development of a novel expression vector incorporating optimized transcriptional regulatory elements such as a truncated FVII promoter, specific enhancers, introns, and locus control regions to enhance liver-specific gene expression, including the use of UTRs and LCRs to stabilize mRNA and improve protein translation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional expression vectors are used for gene therapy in the liver, then initial gene expression can be achieved, but the expression level is transient and not sustained over time
Solution Approach 1:
The patent incorporates LCRs and specific enhancer elements into the expression vector design before viral delivery, creating a pre-configured regulatory architecture that enables sustained expression from the outset. The LCR upstream of the albumin promoter is designed to establish long-term transcriptional activity before immune responses can eliminate the vector
Solution Approach 2:
The patent modifies key transcriptional regulatory parameters by using a truncated FVII promoter (−108 to +60) combined with specific enhancer sequences (PAH and AMBP) and LCR elements. These parameter changes in the regulatory architecture transform the transient expression profile into a sustained expression pattern that maintains therapeutic levels over extended periods
2Reliability
If high doses of virus carrying therapeutic genes are injected to achieve effective expression levels, then therapeutic effect can be improved, but immune response against the vector increases
Solution Approach 1:
The patent changes the immunogenicity parameter by using liver-specific promoters (FVII, albumin) and enhancer sequences that restrict viral gene expression primarily to hepatocytes. This tissue-specific parameter change reduces exposure of non-liver tissues to viral antigens, thereby lowering the overall immune response while maintaining effective therapeutic expression levels in the target organ
3Adaptability or versatility
If tissue-specific promoters are used to achieve liver-specific expression, then expression specificity is improved, but expression level may be insufficient for therapeutic effect
Solution Approach 1:
The patent merges multiple regulatory elements with complementary functions: the FVII promoter provides liver-specificity, the albumin LCR provides high-level sustained expression, and the PAH/AMBP enhancers amplify transcriptional activity. This combination merges the advantages of specificity and high expression level that individually conflicting elements could not achieve alone
Solution Approach 2:
The expression vector employs a composite regulatory architecture combining heterogeneous DNA elements (truncated FVII promoter, albumin LCR, PAH enhancer, AMBP enhancer, intron sequences) that work synergistically. This composite design achieves both tissue-specificity and high expression levels by integrating the functional properties of each individual element
4Reliability
If existing expression vectors are used in clinical trials, then some therapeutic benefit can be achieved, but expression levels remain below the threshold for effective treatment
Solution Approach 1:
The patent changes the expression quantity parameter by optimizing the promoter configuration (truncated FVII at −108 to +60), incorporating strong enhancer elements (PAH and AMBP sequences), and adding LCR regions upstream of the albumin promoter. These parameter changes in the transcriptional regulatory architecture collectively amplify gene expression to achieve blood concentration levels above the 500 ng/ml threshold required for effective hemophilia B treatment
Data Source
AI summary
Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.